Analysis of side effects during COVID-19 pharmacotherapy

• Nadezhda I. Baranova
• Lyudmila A. Aschina

Abstract

The issues of adverse effects of pharmacotherapy on the organism of COVID-19 patients are actively discussed by scientists all over the world. In this regard, of particular interest are studies examining adverse reactions associated with pharmacokinetics and pharmacogenetics of drugs used to treat COVID-19.

The aim of the study was to analyze side effects during COVID-19 pharmacotherapy.

Material and methods. A search of scientific literature was carried out for 2019–2022 in electronic databases: PubMed, eLIBRARY, Scopus, Web of Science Core Collection, Google Scholar. A total of 152 publications were studied, 34 papers were selected for analysis.

Results and discussion. A review of the results of scientific researches on the study of adverse reactions during the treatment of patients with COVID-19 with antiviral drugs, glucocorticosteroids, oral anticoagulants is presented. An important aspect of the safety of pharmacotherapy in COVID-19 remains drug interactions with P-glycoprotein and/or enzymes of the cytochrome P450 system. One of the possible causes of variability in the clinical effect of therapy may be pharmacogenetics features of the organism, which can be analyzed to assess individual responses to COVID-19 treatment. In this regard, it seems relevant to take into account clinically relevant markers of the severe course of COVID-19, which will improve the efficacy and safety of treatment of the new coronavirus infection.

Keywords:unwanted adverse reactions; pharmacotherapy; pharmacogenetics; antiviral drugs; COVID-19

References

1. Simbirtsev A.S. Immunopathogenesis and prospects for immunotherapy of coronavirus infection. VICH infektsiya i immunosupressii [HIV Infection and Immunosuppression]. 2020; 12 (4): 7–22. DOI: https//doi.org/10.22328/2077-9828-2020-12-4-7-22 (in Russian)

2. Kononenko A.A., Noskov A.K., Vodyanitskaya S.Yu., Podoynitsyna O.A. Human coronaviruses capable of causing emergencies. Meditsinskiy vestnik Yuga Rossii [Medical Bulletin of the South of Russia]. 2021; 12 (1): 14–23. (in Russian)

3. Swapan K.C., Snigdha S., Maria N.M. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci. 2020; 7: 196. DOI: https//doi.org/10.3389/fmolb.2020.00196

4. Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini. E. A comprehensive review of COVID-19 characteristics. Biol Proced Online. 2020; 22: 19. DOI: https//doi.org/10.1186/s12575-020-00128-2

5. Order «On Approval of Pharmacovigilance Procedure». 15.02.2017. No. 1071. Registered with the Ministry of Justice of Russia on March 20, 2017 No. 46039. (in Russian)

6. Hossen M.S., Barek M.A., Jahan N., Safiqul I.M. A Review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med. 2020; 2 (10): 1777–89. DOI: https//doi.org/10.1007/s42399-020-00485-9

7. Provisional Methodological Recommendations «Prevention, Diagnosis and Treatment of New Coronavirus Infection (COVID-19)». Version 16 of 18.08.22. (in Russian)

8. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020; 383 (19): 1813–26. DOI: https//doi.org/10.1056/NEJMoa2007764

9. Kim K.H. COVID-19. Int Neurourol J. 2020; 24 (1): 1. DOI: https//doi.org/10.5213/inj.2020edi.001

10. Chen G.L., Li X.F., Dai X.H., Li N., Cheng M.L., Huang Z., et. al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe. 2022; 3 (3): 193–202. DOI: https//doi.org/10.1016/S2666-5247(21)00280-9

11. Paladugu S., Donato A. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. Ann Intern Med. 2020; 173 (2): JC4. DOI: https//doi.org/10.7326/ACPJ202007210-005

12. Tsvetov V.M., Mirzaev K.B., Sychev D.A. Possibility and prospects of using remdesivir in patients with COVID-19. Kachestvennaya klinicheskaya praktika [Qualitative Clinical Practice]. 2020; (S4): 99–102. DOI: https//doi.org/10.37489/2588-0519-2020-S4-99-102 (in Russian)

13. Svetlitskaya O.I., Eremin S.V., Sirosh Yu.A., Sharanova O.A., Kendenkov O.I. Role of remdesivir in the treatment of patients with COVID-19-associated acute respiratory distress syndrome. Mezhdunarodniy nauchno-issledovatel’skiy zhurnal [International Scientific Research Journal]. 2022; 4 (118): 86–8. DOI: https://doi.org/10.23670/IRJ.2022.118.4.086 (in Russian)

14. Chen Y.Z, Lin M.S., Lin Y.P., Liu Y.Z., Yang C.J. Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate. J Microbiol Immunol Infect. 2023; 23: 1684–82. DOI: https//doi.org/10.1016/j.jmii.2023.06.004

15. Manabe T., Kambayashi, D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21 (1): 489. DOI: https://doi.org/10.1186/s12879-021-06164-x

16. Leonova M.V. Repurposed antimicrobials and antivirals for the treatment of COVID-19: safety and side effects in real-world clinical practice (scientific review). Consilium Medicum. 2022; 24 (9): 567–73. DOI: https//doi.org/10.26442/20751753.2022.9.201763 (in Russian)

17. Shinkai M., Tsushima K., Tanaka S., Hagiwara E., Tarumoto N., Kawada I., et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infect Dis Ther. 2021; 10 (4): 2489–509. DOI: https//doi.org/ 10.1007/s40121-021-00517-4

18. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020; 10: 1192–8. DOI: https//doi.org/10.1016/j.eng.2020.03.007

19. Alotaibi M., Ali A., Alatawi D.B., Alotaibi S., Alhifany A., et al. Effectiveness and safety of favipiravir compared to hydroxychloroquine for management of Covid-19: a retrospective study. Int J Gen Med. 2021; 14: 5597–606. DOI: https//doi.org/10.2147/IJGM.S329881

20. Balakin K.V., Storozhenko R.V., Yakubova E.V. Favipiravir as COVID-19 therapy. Nauchniy byulleten’ KhimRar [KhimRar Scientific Bulletin]. 2023; (1): 1–26. (in Russian)

21. Al-Muhsen S., Al-Numair N.S., Sharif-Askari N.S., Basamh R., Alyounes B., Jabaan A., et al. Favipiravir effectiveness and safety in hospitalized moderate-severe COVID-19 patients: observational prospective multicenter investigation in Saudi Arabia. Front Med. (Lausanne). 2022; 9: 826247. DOI: https//doi.org/10.3389/fmed.2022.826247

22. Doi Y., Hibino M., Hase R., Yamamoto M., Kasamatsu Y., Hirose M., et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020; 64 (12): e01897-20. DOI: https//doi.org/10.1128/AAC.01897-20

23. Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020; 6 (2): 45–51. DOI: https//doi.org/ 10.1016/S2055-6640(20)30016-9

24. Khokhlov A.L., Rybachkova Yu.V. The use of the new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective. Kachestvennaya klinicheskaya praktika [Qualitative Clinical Practice]. 2022; (3): 35–51. DOI: https//doi.org/0.37489/2588-0519-2022-3-35-51 (in Russian)

25. The Recovery Collaborative Group’s scientific Contributions. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022; 399 (10 320): 143–51. DOI: https//doi.org/10.1016/S0140-6736 (21)01825-01830

26. Piazza G., Morrow D.A. Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA. 2020; 324 (24): 2548–9. DOI: https//doi.org/10.1001/jama.2020.23422

27. Levi M., Thachil J., Iba T., Levy J.H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020; 7 (6): 438–40. DOI: https//doi.org/10.1016/S2352-3026(20)30145-9

28. Ruzhentsova T.A., Khavkina D.A., Chukhlyaev P.V., Garbuzov A.A., Ploskireva A.A. Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients. Voprosy virusologii [Problems of Virology]. 2021; 66 (1): 40–6. DOI: https//doi.org/10.36233/0507-4088-14 (in Russian)

29. Goligher E.C., Bradbury C.A., McVerry B.J., Lawler P.R., Berger J.S., Gong M.N., et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021; 385 (9): 777–89. DOI: https//doi.org/10.1056/NEJMoa2103417

30. Alshabeeb M.A., Alyabsi M., Aziz M.A., Abohelaika S. Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB. Front Med. 2022; 9: 1–12. DOI: https://doi.org/10.3389/fmed.2022.1001876

31. Zubiaur P., Koller D., Saiz-Rodríguez M., Navares-Gómez M., Abad-Santos F. Important pharmacogenetic information for drugs prescribed during the SARS-CoV-2 infection (COVID-19). Clin Transl Sci. 2020; 13 (6): 1023–33. DOI: https//doi.org/10.1111/cts.12866

32. Timasheva Ya.R., Nasibullin T.R., Erdman V.V., Tuktarova I.A., Mustafina O.E. Pharmacogenetic variability in three Russian populations: age-related aspects. Farmakogenetika i farmakogenomika [Pharmacogenetics and Pharmacogenomics]. 2019; (2): 32–3. DOI: https://doi.org/10.24411/2588-0527-2019-10058 (in Russian)

33. Traspov A.A., Minashkin M.M., Poyarkov S.V., Komarov A.G., Shtinova I.A., Speshilov G.I., et al. RS17713054 and RS1800629 polymorphisms of LZTFL1 and TNF genes are associated with the severity of COVID-19 course. Vestnik RGMU [Bulletin of Russian State Medical University]. 2022; (6): 35–40. DOI: https//doi.org/10.24075/vrgmu.2022.065 (in Russian)

34. Fabrizio C., Termine A., Caputo V., Megalizzi D., Calvino G., Trastulli G., et al. Analysis of genetic variants associated with COVID-19 outcome highlights different distributions among populations. J Pers Med. 2022; 12 (11): 1851. DOI: https//doi.org/10.3390/jpm12111851

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)